The Role of New Imaging Technologies in the Diagnosis of Cardiac Amyloidosis

Heart Fail Clin. 2022 Jan;18(1):61-72. doi: 10.1016/j.hfc.2021.07.014. Epub 2021 Oct 25.

Abstract

Cardiac amyloidosis is an infiltrative disorder caused by transthyretin or immunoglobulin free light-chain deposition, which determines clinical disease with similar phenotype but different time course, prognosis and therapy. Multimodality imaging is the cornerstone for disease diagnosis and management. Multimodality imaging has revolutionized the approach to the disease favoring its awareness and simplifying its diagnosis, especially in ATTR cardiac amyloidosis. This describes the different imaging tools, from the traditional to the more novel ones, and highlights the different approach in each different setting (prognosis, subtyping, prognosis, monitoring disease progression, and response to therapy).

Keywords: Cardiac amyloidosis; Cardiac magnetic resonance; Echocardiography; Multimodality imaging; Nuclear imaging.

Publication types

  • Review

MeSH terms

  • Amyloidosis* / diagnostic imaging
  • Cardiomyopathies* / diagnostic imaging
  • Echocardiography
  • Humans
  • Multimodal Imaging
  • Prognosis